The Role of P53 in Determining Sensitivity to Radiotherapy

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2003 Feb 4

PMID 12563311

Citations 245

Authors

Andrei V Gudkov

Elena A Komarova

Affiliations

Soon will be listed here.

Abstract

Ionizing radiation (IR) has proven to be a powerful medical treatment in the fight against cancer. Rational and effective use of its killing power depends on understanding IR-mediated responses at the molecular, cellular and tissue levels. Tumour cells frequently acquire defects in the molecular regulatory mechanisms of the response to IR, which sensitizes them to radiation therapy. One of the key molecules involved in a cell's response to IR is p53. Understanding these mechanisms indicates new rational approaches to improving cancer treatment by IR.

Citing Articles

Novel Camptothecin Derivative 9c with Enhanced Antitumor Activity via NSA2-EGFR-P53 Signaling Pathway.

Du F, Zhang A, Qi X, Yin R, Jiang T, Li J Int J Mol Sci. 2025; 26(5).

PMID: 40076615 PMC: 11900506. DOI: 10.3390/ijms26051987.

Aberrant DNA methylation as a key modulator of cell death pathways: insights into cancer progression and other diseases.

Zahoor A, Khazer R, Mehraj I, Gani U, Fayaz F, Khanday F Funct Integr Genomics. 2025; 25(1):50.

PMID: 40024973 DOI: 10.1007/s10142-025-01552-x.

TP53 Deficiency in the Natural History of Prostate Cancer.

Ofner H, Kramer G, Shariat S, Hassler M Cancers (Basel). 2025; 17(4).

PMID: 40002239 PMC: 11853097. DOI: 10.3390/cancers17040645.

USP5 Binds and Stabilizes EphA2 to Increase Nasopharyngeal Carcinoma Radioresistance.

Tang J, Peng Y, Zhu W, Qiu J, Huang W, Yi H Int J Biol Sci. 2025; 21(3):893-909.

PMID: 39897046 PMC: 11781186. DOI: 10.7150/ijbs.102461.

Mutant p53 regulates a distinct gene set by a mode of genome occupancy that is shared with wild type.

Rahme R, Resnick-Silverman L, Anguiano V, Campbell M, Fenaux P, Manfredi J EMBO Rep. 2025; 26(5):1315-1343.

PMID: 39875582 PMC: 11893899. DOI: 10.1038/s44319-025-00375-y.